EUVIMEDEUVIMED entdecken
Crossref

Development of a circulating tumor DNA methylation biomarker panel for hepatocellular carcinoma detection

Yanzhao Zhou, Beilin Zhang, Ke Yang, Zhengzheng Wang, Qingjun Li, Weizhen Wang, Dongxu Chen, Jie Ma, Jinxue Zhou

European Journal of Surgical Oncology · 2026

DOI: 10.1016/j.ejso.2025.111167 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Surgical Oncology, 2026. Verfasst von Yanzhao Zhou und 8 weiteren Autor:innen. Beteiligte Einrichtung: University of Electronic Science and Technology of China, Chengdu, 611731, China; Department of Hepatobiliary and Pancreatic Surgery, The Affiliated …. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, DNA Methylation, Biomarkers, Tumor. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Henan Provincial Science and Technology Research Project, Henan Medical Science and Technique Foundation, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide. Early detection is crucial for improving the overall survival rates in patients diagnosed with HCC. MATERIALS AND METHODS: In this study, we developed a novel methylation-based gene panel for HCC detection using a large cohort of 149 patients with HCC and 270 controls, which included 109 healthy individuals, 102 patients with benign liver diseases, and 59 patients with non-hepatic malignancies. The diagnostic performance of the panel was assessed by generating receiver operating characteristic (ROC) curves to determine the area under the curve (AUC), sensitivity, specificity, and corresponding 95 % confidence intervals (CIs). All statistical figures were generated using GraphPad Prism software. RESULTS: Our analysis revealed significantly elevated methylation levels of SEPTIN9, Suppressor of Cytokine Signaling 1 (SOCS1), and Cyclooxygenase-2 (COX2) in HCC patients compared to those in all control groups. The panel demonstrated strong diagnostic performance, achieving an AUC of 0.907 (95 % CI: 0.876-0.933), with a sensitivity of 83.9 % (95 % CI: 77.0-89.4 %) and a specificity of 88.5 % (95 % CI: 84.1-92.1 %). Importantly, it exhibited high diagnostic efficacy for early stage HCC, achieving sensitivities of 75.0 % for stage I and 84.0 % for stage II. Comparisons with pathological findings yielded a kappa value of 0.72, indicating a substantial agreement with the gold standard. CONCLUSION: These findings suggest that the DNA methylation biomarkers panel could revolutionize HCC diagnostics by enabling earlier, more accurate, and cost-effective detection, particularly in high-risk populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsDNA MethylationBiomarkers, TumorCirculating Tumor DNAHumansMaleFemaleSeptinsMiddle AgedCyclooxygenase 2Suppressor of Cytokine Signaling 1 ProteinROC CurveAgedCase-Control StudiesAdultSensitivity and SpecificityEarly Detection of Cancer

Stichwörter der Autor:innen

Circulating tumor DNADNA methylationEarly-stage detectionHepatocellular carcinomaLiquid biopsy

Substanzen

Biomarkers, TumorSeptinsSEPTIN9 protein, humanCyclooxygenase 2Suppressor of Cytokine Signaling 1 ProteinSOCS1 protein, humanCirculating Tumor DNAPTGS2 protein, human

Autor:innen und Institutionen

  • University of Electronic Science and Technology of China, Chengdu, 611731, China; Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zheng…
  • Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450008, China.
  • Department of Molecular Pathology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450008, China; Henan Key Laboratory of Molecular Pathology, Zhengzhou, 450008, China.
  • Department of Molecular Pathology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450008, China; Henan Key Laboratory of Molecular Pathology, Zhengzhou, 450008, China. Electro…
  • Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450008, China. Electronic address: zhoujx888@126.com.

Förderung

  • Henan Provincial Science and Technology Research Project
  • Henan Medical Science and Technique Foundation
  • National Natural Science Foundation of China

Zitieren

APA

Zhou, Y., Zhang, B., Yang, K., Wang, Z., Li, Q., Wang, W., Chen, D., Ma, J., & Zhou, J. (2026). Development of a circulating tumor DNA methylation biomarker panel for hepatocellular carcinoma detection. European Journal of Surgical Oncology. https://doi.org/10.1016/j.ejso.2025.111167

Vancouver

Zhou Y, Zhang B, Yang K, Wang Z, Li Q, Wang W, et al. Development of a circulating tumor DNA methylation biomarker panel for hepatocellular carcinoma detection. European Journal of Surgical Oncology. 2026. doi:10.1016/j.ejso.2025.111167

BibTeX
@article{Zhou2026,
  author = {Zhou, Yanzhao and Zhang, Beilin and Yang, Ke and Wang, Zhengzheng and Li, Qingjun and Wang, Weizhen and Chen, Dongxu and Ma, Jie and Zhou, Jinxue},
  title = {Development of a circulating tumor DNA methylation biomarker panel for hepatocellular carcinoma detection},
  journal = {European Journal of Surgical Oncology},
  year = {2026},
  doi = {10.1016/j.ejso.2025.111167}
}
Kostenlos starten →